Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
132 USD | +0.15% | +6.74% | +21.03% |
Mar. 28 | Robert Davis, Merck CEO: Another obesity drug? | MT |
Mar. 28 | Merck: new indication approved for Keytruda in Europe | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.03% | 334B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B | |
-1.28% | 152B |
- Stock
- Equities
- Stock Merck & Co., Inc. - Nyse
- News Merck & Co., Inc.
- Merck : RBC Capital Adjusts Merck & Company PT to $77 From $79, Maintains Sector Perform Rating